CA3043300A1 - Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash) - Google Patents

Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash) Download PDF

Info

Publication number
CA3043300A1
CA3043300A1 CA3043300A CA3043300A CA3043300A1 CA 3043300 A1 CA3043300 A1 CA 3043300A1 CA 3043300 A CA3043300 A CA 3043300A CA 3043300 A CA3043300 A CA 3043300A CA 3043300 A1 CA3043300 A1 CA 3043300A1
Authority
CA
Canada
Prior art keywords
nafld
nash
extended
pirfenidone
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3043300A
Other languages
English (en)
French (fr)
Inventor
Juan Socorro Armendariz Borunda
Jose Agustin Rogelio Magana Castro
Nadiel Hernandez Aldana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Excalibur Pharmaceuticals Inc
Original Assignee
Cell Therapy and Technology SA de CV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapy and Technology SA de CV filed Critical Cell Therapy and Technology SA de CV
Publication of CA3043300A1 publication Critical patent/CA3043300A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3043300A 2016-11-11 2017-11-09 Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash) Pending CA3043300A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
MXMX/A/2016/014775 2016-11-11
MX2016014775A MX364040B (es) 2016-11-11 2016-11-11 Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash).
PCT/MX2017/000129 WO2018088886A1 (es) 2016-11-11 2017-11-09 Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash)

Publications (1)

Publication Number Publication Date
CA3043300A1 true CA3043300A1 (en) 2018-05-17

Family

ID=61193005

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3043300A Pending CA3043300A1 (en) 2016-11-11 2017-11-09 Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash)

Country Status (21)

Country Link
US (3) US20190262325A1 (enExample)
EP (1) EP3539537A1 (enExample)
JP (2) JP2019535822A (enExample)
KR (2) KR20190084056A (enExample)
CN (2) CN110248646A (enExample)
AR (1) AR110057A1 (enExample)
AU (3) AU2017358367B2 (enExample)
CA (1) CA3043300A1 (enExample)
CL (1) CL2019001280A1 (enExample)
CO (1) CO2019004799A2 (enExample)
EC (1) ECSP19031851A (enExample)
IL (1) IL266519A (enExample)
JO (1) JOP20190102A1 (enExample)
MA (1) MA45754A1 (enExample)
MX (1) MX364040B (enExample)
PE (1) PE20191149A1 (enExample)
PH (1) PH12019501047A1 (enExample)
RU (1) RU2019116422A (enExample)
UY (1) UY37478A (enExample)
WO (1) WO2018088886A1 (enExample)
ZA (1) ZA201903012B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
CN111386115A (zh) * 2017-11-28 2020-07-07 艾格尔峰生物制药有限公司 用于治疗非酒精性脂肪性肝炎的方法和药物组合物
WO2020115774A1 (en) 2018-12-06 2020-06-11 Cipla Limited High drug load extended release formulations
AU2021365528A1 (en) * 2020-10-23 2023-06-15 Hq Han Bifunctional antagonists of tumor necrosis factor-alpha and transforming growth factor-beta and uses thereof
CN116159056A (zh) * 2023-03-09 2023-05-26 中南大学湘雅医院 一种氟非尼酮在制备非酒精性脂肪性肝炎药物中的应用
CN117007806A (zh) * 2023-09-21 2023-11-07 中国人民解放军军事科学院军事医学研究院 靶向肝巨噬细胞内lxr用于控制慢乙肝进展

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60234812D1 (de) * 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
US20080025986A1 (en) * 2003-06-06 2008-01-31 Ozes Osman N Methods of Treating Tnf-Mediated Disorders
CN100542532C (zh) * 2004-05-24 2009-09-23 上海睿星基因技术有限公司 吡非尼酮在制备治疗肝损伤坏死和急性肺损伤的药物中的用途
WO2010048716A1 (en) * 2008-10-29 2010-05-06 Pacific Therapeutics Ltd. Composition and method for treating fibrosis
US7635707B1 (en) * 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
CN101972236A (zh) * 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的缓释制剂
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
CN102488660A (zh) * 2011-12-15 2012-06-13 西安天一秦昆制药有限责任公司 一种含吡非尼酮的缓释微丸
CN103550242B (zh) * 2013-11-22 2015-07-15 四川国康药业有限公司 一种治疗肝纤维化的药物组合物及其制备方法

Also Published As

Publication number Publication date
EP3539537A1 (en) 2019-09-18
AU2017358367A1 (en) 2019-05-30
PH12019501047A1 (en) 2019-12-11
JOP20190102A1 (ar) 2019-05-06
ZA201903012B (en) 2020-09-30
AU2024200737A1 (en) 2024-02-22
MX2016014775A (es) 2018-05-10
RU2019116422A3 (enExample) 2021-04-09
JP2019535822A (ja) 2019-12-12
CO2019004799A2 (es) 2019-07-31
MA45754A1 (fr) 2019-12-31
AR110057A1 (es) 2019-02-20
PE20191149A1 (es) 2019-09-02
US20250325530A1 (en) 2025-10-23
AU2017358367B2 (en) 2023-11-09
CN110248646A (zh) 2019-09-17
RU2019116422A (ru) 2020-12-11
KR20190084056A (ko) 2019-07-15
ECSP19031851A (es) 2019-06-30
KR20240065330A (ko) 2024-05-14
UY37478A (es) 2018-05-31
MX364040B (es) 2019-04-11
CN115969802A (zh) 2023-04-18
US20230181550A1 (en) 2023-06-15
JP2022173344A (ja) 2022-11-18
IL266519A (en) 2019-07-31
CL2019001280A1 (es) 2019-07-19
WO2018088886A1 (es) 2018-05-17
AU2026200298A1 (en) 2026-02-05
US20190262325A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
US20250325530A1 (en) Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash)
US11291694B2 (en) Composition for treating or preventing metabolic disease, containing, as active ingredient, extracellular vesicles derived from Akkermansia muciniphila bacteria
Cariou et al. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review
Zhang et al. Sodium butyrate improves liver glycogen metabolism in type 2 diabetes mellitus
Jang et al. The role of mitochondria in aging
Ji et al. Daphnetin ameliorates experimental colitis by modulating microbiota composition and Treg/Th17 balance
Tao et al. Inhibition of Th1/Th17 responses via suppression of STAT1 and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside icariin
Hagenlocher et al. Cinnamon extract reduces symptoms, inflammatory mediators and mast cell markers in murine IL-10−/− colitis
JP6542275B2 (ja) ＧＰＣＲ１９作用剤を有効成分として含有するアレルギー性皮膚疾患の予防又は治療用の組成物｛Ｃｏｍｐｏｓｉｔｉｏｎ ｆｏｒ ｐｒｅｖｅｎｔｉｎｇ ｏｒ ｔｒｅａｔｉｎｇ ａｌｌｅｒｇｉｃ ｄｅｒｍａｔｉｔｉｓ ｃｏｍｐｒｉｓｉｎｇ ＧＰＣＲ１９ ａｇｏｎｉｓｔ ａｓ ａｎ ａｃｔｉｖｅ ｉｎｇｒｅｄｉｅｎｔ｝
Kaneko et al. Preventive effect of TU‐100 on a type‐2 model of colitis in mice: possible involvement of enhancing adrenomedullin in intestinal epithelial cells
Grytten et al. Inflammatory markers after supplementation with marine n-3 or plant n-6 PUFAs: A randomized double-blind crossover study
CN109550051B (zh) 组蛋白去甲基化酶kdm6a抑制剂在制备肥胖症治疗药物的用途
Li et al. The synergism of Lactobacillaceae, inulin, polyglucose, and aerobic exercise ameliorates hyperglycemia by modulating the gut microbiota community and the metabolic profiles in db/db mice
Dai et al. Toll‐Like Receptor 4–Myeloid Differentiation Primary Response Gene 88 Pathway Is Involved in the Shikonin Treatment of CIA by Regulating Treg/Th17 Expression
KR20150050406A (ko) 니코틴아마이드 라이보사이드를 유효성분으로 포함하는 패혈증 치료 또는 예방용 약제학적 조성물
WO2007132900A1 (ja) 皮膚保湿剤および皮膚炎治療剤
Kim et al. Hydrangenol, an active constituent of Hydrangea serrata (Thunb.) Ser., ameliorates colitis through suppression of macrophage-mediated inflammation in dextran sulfate sodium-treated mice
Zhang et al. The heterogeneity of monocyte-derived macrophages in MASH pathogenesis
KR101706868B1 (ko) 2-아미노-2-노보네인카복실산을 함유하는 지방간염의 예방 또는 치료용 조성물
HK40092172A (zh) 含吡非尼酮缓释组合物用於治疗和逆转人脂肪性肝炎的药物用途
RU2807743C1 (ru) Применение 5-пентадецилрезорцинола для повышения доли Akkermansia muciniphila в микробиоме человека
Abd-Elsattar et al. A Histological Study of The Protective Role of Intermittent Fasting and Probiotics on Indomethacin Induced Colitis in Adult Male Albino Rats
Gulliver et al. Effective treatment of chronic hand dermatitis with 36 continuous months of alitretinoin administration: report of three cases
CN119970721A (zh) 吲哚乙酸在制备预防和/或治疗脂肪肝肝纤维化药物中的应用
Kobayashi et al. Influence of the Digested Products of Royal Jelly on Insulin Levels in KK-Ay Mice

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220902

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241101

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241101

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241101

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NOTICE OF ALLOWANCE IS ISSUED

Effective date: 20250526

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250526